WHO to study whether three drugs, including J&J's Remicade, can help hospitalized COVID-19 patients

The World Health Organization plans to test three new drugs as possible treatments for people who have been hospitalized for COVID-19. This includes Ipca Laboratories Ltd.'s malaria drug artesunate; Novartis AG's cancer medication Gleevec; and Johnson & Johnson's rheumatoid arthritis drug Remicade. All of the drugs are already in use for other reasons. There are still few therapies that effectively treat COVID-19 patients, especially those who have severe enough disease that they end up hospitalized. "Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need," WHO director-general Tedros Adhanom Ghebreyesus said in a news release. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

WHO to study whether three drugs, including J&J's Remicade, can help hospitalized COVID-19 patients
The World Health Organization plans to test three new drugs as possible treatments for people who have been hospitalized for COVID-19. This includes Ipca Laboratories Ltd.'s malaria drug artesunate; Novartis AG's cancer medication Gleevec; and Johnson & Johnson's rheumatoid arthritis drug Remicade. All of the drugs are already in use for other reasons. There are still few therapies that effectively treat COVID-19 patients, especially those who have severe enough disease that they end up hospitalized. "Finding more effective and accessible therapeutics for COVID-19 patients remains a critical need," WHO director-general Tedros Adhanom Ghebreyesus said in a news release. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.